Table 1 Baseline demographics and disease characteristics for factors used to create propensity score for matching at diagnosis and 5 years after diagnosis without recurrence within 5 years.
From: Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
Entire population | Parent cohort (at diagnosis) | Late relapse cohort (5 years after diagnosis) | |
|---|---|---|---|
Characteristics | Number (%) of patients | Number (%) of patients | Number (%) of patients |
Total number | |||
Case:control pairs | Not applicable | 249 | 17 |
Patients | 4994 | 498 | 34 |
Age group (years) | |||
<40 | 627 (13) | 74 (15) | – |
40 to <65 | 3895 (78) | 364 (73) | 26 (76) |
≥65 | 472 (9) | 60 (12) | 8 (24) |
Menopausal status | |||
Pre/peri | 2387 (48) | 228 (46) | 9 (26) |
Post | 2564 (52) | 270 (54) | 25 (74) |
ERPgR status | |||
ER and PgR negative | 1796 (36) | 180 (36) | 2 (6) |
ER and/or PgR positive | 3198 (64) | 318 (64) | 32 (94) |
Tumor size | |||
≤2 cm | 1933 (39) | 83 (17) | 6 (17) |
>2 to ≤5 cm | 2552 (51) | 334 (67) | 23 (68) |
>5 cm | 503 (10) | 81 (16) | 5 (15) |
Nodal status | |||
Negative | 1300 (26) | 74 (15) | 4 (12) |
1–3 | 2139 (43) | 157 (32) | 5 (15) |
4+ | 1555 (31) | 267 (53) | 25 (74) |
Histologic grade | |||
I | 422 (9) | 15 (3) | 6 (18) |
II | 1628 (33) | 153 (31) | 16 (47) |
III | 2833 (58) | 330 (66) | 12 (35) |
Treatmenta | |||
No bevacizumab | 1000 (20) | 96 (19) | 5 (15) |
Bevacizumab | 3994 (80) | 402 (81) | 29 (85) |
